Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 31,249 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded up $1.04 during trading hours on Monday, hitting $98.64. The company’s stock had a trading volume of 542,455 shares, compared to its average volume of 989,323. The company has a market cap of $5.39 billion, a PE ratio of -23.88 and a beta of 1.20. The business has a 50 day moving average price of $87.77 and a two-hundred day moving average price of $71.95. Dianthus Therapeutics, Inc. has a 12-month low of $18.08 and a 12-month high of $102.33.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on DNTH shares. William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $117.82.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares during the last quarter. American Century Companies Inc. increased its stake in Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after acquiring an additional 6,323 shares during the last quarter. Invesco Ltd. increased its stake in Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after acquiring an additional 4,962 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after acquiring an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.